*1 Anthony, B. ;Merina, B.; Iyer, V.S.; Judy, N.; Lennertz, K.; Joyal, S. (2008) A pilot cross-over study to evaluate human oral bioavailablability of BMC-95 CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian Journal of Pharmaceutical Sciences 70;445-449
*2 Chandran, B. and Goel, A. (2012) A randomized, pilot study to assess the efficacy and safety of curcumin in patiënts with active rheumatoid arthritis. Phytotherapy Research 26;1719-1725.
*3 Colitti, M.; Gaspardo, B.; Della Pria, A.; Scaina, C.; Stefanon, B. (2012) Transcriptome modification of white blood cells after dietary administration of curcumin and non-steroidal anti-inflammatory drug in osteoarthritic affected dogs. Veterinary Immunology and Immunopathology 147;136-146.
*4 Mobasheri, A.; Henrotin, Y.; Biesalki, H.-K.; Shakibaei, M. (2012) Scientific evidence and rationale for the development of curcumin and resveratrol as nutraceuticals for joint health. International Journal of Molecular Sciences 13;4202-4232.
*5 Zhou, H.; Beevers, C.S.;Huang, S. (2011) Targets of curcumin. Current Drug Targets 12;332-347.
*6 Mathy-Hartert, M.: Jacquemont-Collet, I.; Priem, F.; Sanchez, C.; Lambert, C.; Henrotin, Y. (2009) Curcumin Inhibits pro-inmlaffatory mediators and metelloproteinase-3 production by chondrocytes. Inflammation Research 58;899-908
*7 Henrotin, Y.; Clutterbuck, A.L.; Allaway, D.: Lodwig, E.M.; Harris, P.; Mathy-Hartert, M.; Shakibaei, M.; Mobasheri, A. (2010) Biological actions of curcumin on articular chondrocytes. Osteoarthritis and Cartilage 18;141-149.
*8 Kumar, D.; Kumar, M.; Saravanan, C.; Kumr Singh, S. (2012) Curcumin: a potential candidate for matrix metalloproteinase inhibitors. Expert Opinion on Therapeutic Targets 16;959-972.